Drugs for exceptionally rare diseases: a commentary on Hughes et al

K. Claxton; C. McCabe; A. Tsuchiya; J. Raftery

Drugs for exceptionally rare diseases: a commentary on Hughes et al

K. Claxton, C. McCabe, A. Tsuchiya, J. Raftery

Economics

Research output: Working paper › Discussion paper

Abstract

Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.

Original language	English
Publisher	QJM
Publication status	Published - 2006

Access to Document

HEDS_DP_06-02.pdf

Cite this

@techreport{faf0185ca151467cbada60bdd70eebce,

title = "Drugs for exceptionally rare diseases: a commentary on Hughes et al",

abstract = "Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.",

author = "K. Claxton and C. McCabe and A. Tsuchiya and J. Raftery",

year = "2006",

language = "English",

publisher = "QJM",

type = "WorkingPaper",

institution = "QJM",

}

TY - UNPB

T1 - Drugs for exceptionally rare diseases: a commentary on Hughes et al

AU - Claxton, K.

AU - McCabe, C.

AU - Tsuchiya, A.

AU - Raftery, J.

PY - 2006

Y1 - 2006

N2 - Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.

AB - Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.

M3 - Discussion paper

BT - Drugs for exceptionally rare diseases: a commentary on Hughes et al

PB - QJM

ER -